Inozyme Pharma, Inc.
INZY
$1.26
-$0.23-15.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -102.02M | -96.49M | -88.56M | -77.11M | -71.17M |
| Total Depreciation and Amortization | 742.00K | 774.00K | 787.00K | 808.00K | 833.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.66M | 2.69M | 1.42M | 1.17M | 2.74M |
| Change in Net Operating Assets | 4.71M | 1.82M | 805.00K | -2.30M | -3.08M |
| Cash from Operations | -91.91M | -91.21M | -85.55M | -77.44M | -70.68M |
| Capital Expenditure | -62.00K | -150.00K | -144.00K | -155.00K | -298.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 67.06M | 45.24M | -22.73M | -56.86M | -53.35M |
| Cash from Investing | 67.00M | 45.09M | -22.88M | -57.02M | -53.65M |
| Total Debt Issued | -- | 12.50M | 12.50M | 20.00M | 40.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.40M | 11.16M | 70.35M | 86.03M | 85.97M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11.40M | 23.66M | 82.85M | 106.03M | 125.97M |
| Foreign Exchange rate Adjustments | 4.00K | 142.00K | -39.00K | -27.00K | -18.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.51M | -22.32M | -25.61M | -28.45M | 1.63M |